Department of Infection, Immunity and Inflammation, University of Leicester, University Road, Leicester LE1 9HN, UK.
Int J Mol Med. 2010 Mar;25(3):307-13. doi: 10.3892/ijmm_00000346.
Complement-dependent cytotoxicity is one of the mechanisms by which therapeutic monoclonal antibodies are successful against cancer. Complement is one of the innate immune defence systems, whose activation products and membrane-bound regulators interact with cells of the adaptive immune response. The complement system is currently undergoing a re-appreciation in its role within the immune surveillance of tumour. The majority of human tumours are low immunogenic. Complement may be involved through direct, 'danger signal'-elicited activation or via infiltration of inflammatory cells, which express complement components. Inflammatory cells may be associated with malignant transformation and tumour regression. The evidence for the effects of complement activation and regulation on tumour progression and expansion will be reviewed using in vivo, in vitro, and patient studies, and conclusions drawn for the implications in therapy and management of tumour patients.
补体依赖性细胞毒性是治疗性单克隆抗体对抗癌症成功的机制之一。补体是先天免疫防御系统之一，其激活产物和膜结合调节剂与适应性免疫反应的细胞相互作用。补体系统在肿瘤免疫监视中的作用正在重新得到重视。大多数人类肿瘤的免疫原性较低。补体可能通过直接的“危险信号”诱导激活或通过表达补体成分的炎症细胞浸润而发挥作用。炎症细胞可能与恶性转化和肿瘤消退有关。本文将通过体内、体外和患者研究，综述补体激活和调节对肿瘤进展和扩张的影响，并得出对肿瘤患者治疗和管理的意义的结论。
